SCHEMBL18003191

SCHEMBL18003191

Cc1c(C=O)nc(-c2ccc(Cl)cc2)n1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
KDM4E B2RXH2 3/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
GAA P10253 1/20 0.54
PTGS2 P35354 8/20 0.46
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
NPC1 O15118 1/20 0.40
S1PR2 O95136 1/20 0.40
TDP2 O95551 1/20 0.40
S1PR4 O95977 1/20 0.40
RAF1 P04049 1/20 0.40
POLB P06746 1/20 0.40
THRB P10828 1/20 0.40
HPGD P15428 1/20 0.40
S1PR1 P21453 1/20 0.40
MAPK1 P28482 1/20 0.40
CTNNB1 P35222 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18003544 0.83 ALOX5 (0.42) ALDH1A1KDM4EL3MBTL1GAAPTGS2
SCHEMBL8989194 0.83 ADORA2B (0.44) ALDH1A1KDM4EL3MBTL1GAAMEN1
SCHEMBL8989243 0.81 PARP1 (0.44) ALDH1A1KDM4EPTGS2MEN1KMT2A
SCHEMBL8989205 0.80 TDP2 (0.44) ALDH1A1KDM4EPTGS2MEN1KMT2A
SCHEMBL18003325 0.77 PTGS2 (0.46) ALDH1A1KDM4EL3MBTL1GAAPTGS2
SCHEMBL8341362 0.73 GABRA2 (0.49) KDM4EPTGS2MEN1KMT2ALMNA
SCHEMBL31626536 0.71 L3MBTL1 (0.44) ALDH1A1KDM4EL3MBTL1GAAMEN1
SCHEMBL18003007 0.70 NOTUM (0.46) ALDH1A1PTGS2MEN1KMT2AMAPT
SCHEMBL18003730 0.68 KDM4E (0.48) ALDH1A1KDM4EL3MBTL1GAAMEN1
SCHEMBL18003691 0.68 GABRA2 (0.62) KDM4EPTGS2MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 ALDH1A1 1611/4885KDM4E 2681/4885L3MBTL1 1503/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 ALDH1A1 1611/4885KDM4E 2681/4885L3MBTL1 1503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.